Luz Paulo, Dias David, Fortuna Ana, Bretes Luis, Gosalbez Beatriz
Medical Oncology, Centro Hospitalar Universitário do Algarve, Faro, Portugal.
F1000Res. 2019 Sep 16;8:1649. doi: 10.12688/f1000research.20509.2. eCollection 2019.
Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC.
三阴性乳腺癌（TNBC）已被证明对新辅助化疗（NACT）有反应。已经确定，对于某些侵袭性乳腺癌亚型，包括HER-2（过表达）和TNBC，实现病理完全缓解（pCR）是预测长期临床反应和生存结果的重要替代指标。如何增加实现pCR的患者数量仍然具有挑战性。铂类新辅助化疗似乎是解决方案的一部分，而卡培他滨是转移性乳腺癌的一种活性药物，但在早期阶段并非标准用药，可能已在辅助治疗中找到了一席之地。在不久的将来，免疫疗法可在早期三阴性乳腺癌中发挥作用。
